• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED CELLEX EXTRACORPOREAL PHOTOPHERESIS SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED CELLEX EXTRACORPOREAL PHOTOPHERESIS SYSTEM Back to Search Results
Catalog Number CELLEX
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Dyspnea (1816)
Event Date 01/18/2024
Event Type  Injury  
Event Description
The customer reported that a pediatric extracorporeal photopheresis (ecp) patient experienced dyspnea following their ecp treatment procedure.The customer reported that the patient was being treated with ecp for acute graft versus host disease.The customer stated that the patient was an inpatient and unwell due to their underlying condition.The customer reported that the patient's ecp treatment procedure was performed in single needle mode due to venous access issues.The customer stated that the patient's ecp treatment procedure was successfully completed.However, the customer reported that the patient was "slightly" over their 15% safe extracorporeal blood volume (ecv) by 2mls.The customer stated that during the patient's ecp treatment procedure 762mls of whole blood was processed and the patient had an end fluid balance of 310mls.The customer reported that the patient was stable throughout their ecp treatment procedure.The customer stated that overnight, several hours post the patient's ecp treatment procedure, the patient complained of dyspnea.The customer reported that the patient's oxygen saturation was satisfactory.The customer stated that the patient was given the diuretic, furosemide (lasix), for their dyspnea.The customer reported that they plan to start fluid restriction with this patient and to also insert an apheresis line to resolve the patient's venous access issue so the patient can carry on with their ecp treatments.The customer stated that the reason for the patient's dyspnea was multicausal as the patient was an acutely ill inpatient due to their underlying condition, on multiple iv therapies for their underlying condition, and their ecp treatment procedure was "slightly" over their 15% safe extracorporeal blood volume (ecv) by 2mls.No product was returned for investigation.
 
Manufacturer Narrative
The system was used for treatment.This case is reportable as a mdr due to the medical intervention of the furosemide that was provided to the patient.Since this event is associated with the treatment, this mdr will be against the instrument.From the instrument perspective, there was no known instrument malfunction and no service was requested by the customer for this adverse event.No product was returned therefore, a device service history review was performed.The instrument has been located at the customer's site since 15-mar-2017.As part of the review, it was determined that the instrument's last service prior to the event was on 28-nov-2023 (annual preventive maintenance).During this service the system checkout procedure was successfully completed indicating that the instrument had passed all tests, met all specifications, and was operational.The root cause for the patient's dyspnea could not be determined as there was no reported instrument malfunction, no product was returned for investigation, and no instrument service was requested by the customer or performed by therakos as a result of this incident.The customer stated that the reason for the patient's dyspnea was multicausal as the patient was an acutely ill inpatient due to their underlying condition, on multiple iv therapies for their underlying condition, and their ecp treatment procedure was "slightly" over their 15% safe extracorporeal blood volume (ecv) by 2mls.Trends were reviewed for complaint category, dyspnea.No trends were detected for this complaint category.The assessment is based on information available at the time of the investigation.Complaints are monitored through tracking and trending.If a trend is detected, further investigation will be conducted.Adverse event term: dyspnea.(b)(4) 29-jan-2024.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CELLEX EXTRACORPOREAL PHOTOPHERESIS SYSTEM
Type of Device
CELLEX EXTRACORPOREAL PHOTOPHERESIS SYSTEM
Manufacturer (Section D)
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
college business & tech park
cruiserath road
blanchardstown, dublin D15 T X2V
EI  D15 TX2V
Manufacturer (Section G)
MACK MOLDING COMPANY
608 warm brook rd
arlington VT 05250
Manufacturer Contact
mark wendelken
440 route 22 east
suite 302
bridgewater, NJ 08807
MDR Report Key18603558
MDR Text Key334034361
Report Number3013428851-2024-00013
Device Sequence Number1
Product Code LNR
UDI-Device Identifier10705030100009
UDI-Public(01)10705030100009(11)170105
Combination Product (y/n)Y
Reporter Country CodeUK
PMA/PMN Number
P860003
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Nurse
Type of Report Initial
Report Date 01/29/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberCELLEX
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 01/19/2024
Initial Date FDA Received01/29/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured01/05/2017
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient SexFemale
-
-